DB
DMRA

Danske Bank’s Damora Therapeutics DMRA Stock Holding History

Danske Bank’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-7
Closed -$85 – 1500
2024
Q3 		$85 Buy
+7
New +$91 ﹤0.01% 1463

Other funds holding DMRA

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

Danske Bank's DMRA Position: Q4 2024 in Review

Danske Bank sold out of Damora Therapeutics (DMRA) in Q4 2024, closing a stake of 7 shares — an estimated $85 sold.

Danske Bank first reported a position in DMRA in Q3 2024 and held it in 1 quarter. The position peaked at $85 in Q3 2024. 10 funds tracked by Wall St. Rank hold DMRA as of Q4 2024.

  • Danske Bank reported no remaining Damora Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Danske Bank sold 7 Damora Therapeutics shares in Q4 2024, an estimated $85.
  • Danske Bank first reported a position in Damora Therapeutics in Q3 2024 and held it in 1 quarter.
  • Danske Bank's Damora Therapeutics position peaked at $85 in Q3 2024.
  • 10 funds tracked by Wall St. Rank held Damora Therapeutics as of Q4 2024.

Based on Danske Bank's 13F filing for Q4 2024, filed 18 Mar 2026.